A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome

Judith Falloon, Joseph Kovacs, Donna O'neill, Michael Polis, Henry Masur, Irwin Feuerstein, Richard T. Davey, H. Clifford Lane, Walter Hughes, Danny Lancaster, Mack Land, Michael Rogers, Stephen Lafon, Carmelita Tuazon, Michael Dohn, Stephen Greenberg

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The drug 566C80 is an investigational hydroxynaphthoquinone that is active against Pneumocystis carinii in vitro and in animal models. Initial studies in humans indicate that 566C80 is safe and has adequate bioavailability after oral administration. We conducted an open-label trial of 566C80 in 34 adults with the acquired immunodeficiency syndrome (AIDS) and untreated pneumocystis pneumonia. All the patients had a partial pressure of arterial oxygen of at least 60 mm Hg while breathing room air. They were enrolled sequentially in three cohorts taking 566C80 at different dosages, all administered orally: 750 mg three times daily for 5 days, then twice daily for 16 days; 750 mg three times daily for 21 days; and 750 mg four times daily for 21 days. All 34 patients survived, and 27 (79 percent) were successfully treated with 566C80 alone. The mean partial pressure of oxygen in 33 patients was 78 mm Hg at entry and 93 mm Hg after the course of 566C80 (P<0.001). In five patients (15 percent) the drug was discontinued because of lack of response. In four patients (12 percent), the drug was discontinued because of toxicity (fever and rash in two patients each). In two of these, treatment was considered to have succeeded because 566C80 was not discontinued because of toxicity until after day 14. Five of the successfully treated patients had rashes that resolved despite continued therapy. In nine patients, serum alanine aminotransferase levels rose above 100 U per liter. During the first three months after the completion of therapy, pneumocystis pneumonia recurred in 4 of the 27 successfully treated patients, and another 3 patients had recurrences between month 3 and month 6 of follow-up. The mean (±SEM) steady-state plasma levels of 566C80 were similar in the three cohorts: 16.3±2.10, 20.4±2.48, and 18.9±3.08 μg per milliliter in the patients taking the drug twice daily, three times daily, and four times daily, respectively. From these preliminary data, the investigational compound 566C80 appears to be a safe, effective, and well-tolerated therapy for P. carinii pneumonia of mild-to-moderate severity in patients with AIDS. (N Engl J Med 1991;325:1534–8.).

Original languageEnglish (US)
Pages (from-to)1534-1538
Number of pages5
JournalNew England Journal of Medicine
Volume325
Issue number22
DOIs
StatePublished - Nov 28 1991

Fingerprint

Atovaquone
Pneumocystis Pneumonia
Acquired Immunodeficiency Syndrome
Therapeutics
Partial Pressure
Exanthema
Pharmaceutical Preparations
Oxygen
Pneumocystis carinii
Alanine Transaminase
Biological Availability

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. / Falloon, Judith; Kovacs, Joseph; O'neill, Donna; Polis, Michael; Masur, Henry; Feuerstein, Irwin; Davey, Richard T.; Lane, H. Clifford; Hughes, Walter; Lancaster, Danny; Land, Mack; Rogers, Michael; Lafon, Stephen; Tuazon, Carmelita; Dohn, Michael; Greenberg, Stephen.

In: New England Journal of Medicine, Vol. 325, No. 22, 28.11.1991, p. 1534-1538.

Research output: Contribution to journalArticle

Falloon, J, Kovacs, J, O'neill, D, Polis, M, Masur, H, Feuerstein, I, Davey, RT, Lane, HC, Hughes, W, Lancaster, D, Land, M, Rogers, M, Lafon, S, Tuazon, C, Dohn, M & Greenberg, S 1991, 'A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome', New England Journal of Medicine, vol. 325, no. 22, pp. 1534-1538. https://doi.org/10.1056/NEJM199111283252202
Falloon, Judith ; Kovacs, Joseph ; O'neill, Donna ; Polis, Michael ; Masur, Henry ; Feuerstein, Irwin ; Davey, Richard T. ; Lane, H. Clifford ; Hughes, Walter ; Lancaster, Danny ; Land, Mack ; Rogers, Michael ; Lafon, Stephen ; Tuazon, Carmelita ; Dohn, Michael ; Greenberg, Stephen. / A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. In: New England Journal of Medicine. 1991 ; Vol. 325, No. 22. pp. 1534-1538.
@article{56682b6e27014f1f845b3cb572b3dea8,
title = "A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome",
abstract = "The drug 566C80 is an investigational hydroxynaphthoquinone that is active against Pneumocystis carinii in vitro and in animal models. Initial studies in humans indicate that 566C80 is safe and has adequate bioavailability after oral administration. We conducted an open-label trial of 566C80 in 34 adults with the acquired immunodeficiency syndrome (AIDS) and untreated pneumocystis pneumonia. All the patients had a partial pressure of arterial oxygen of at least 60 mm Hg while breathing room air. They were enrolled sequentially in three cohorts taking 566C80 at different dosages, all administered orally: 750 mg three times daily for 5 days, then twice daily for 16 days; 750 mg three times daily for 21 days; and 750 mg four times daily for 21 days. All 34 patients survived, and 27 (79 percent) were successfully treated with 566C80 alone. The mean partial pressure of oxygen in 33 patients was 78 mm Hg at entry and 93 mm Hg after the course of 566C80 (P<0.001). In five patients (15 percent) the drug was discontinued because of lack of response. In four patients (12 percent), the drug was discontinued because of toxicity (fever and rash in two patients each). In two of these, treatment was considered to have succeeded because 566C80 was not discontinued because of toxicity until after day 14. Five of the successfully treated patients had rashes that resolved despite continued therapy. In nine patients, serum alanine aminotransferase levels rose above 100 U per liter. During the first three months after the completion of therapy, pneumocystis pneumonia recurred in 4 of the 27 successfully treated patients, and another 3 patients had recurrences between month 3 and month 6 of follow-up. The mean (±SEM) steady-state plasma levels of 566C80 were similar in the three cohorts: 16.3±2.10, 20.4±2.48, and 18.9±3.08 μg per milliliter in the patients taking the drug twice daily, three times daily, and four times daily, respectively. From these preliminary data, the investigational compound 566C80 appears to be a safe, effective, and well-tolerated therapy for P. carinii pneumonia of mild-to-moderate severity in patients with AIDS. (N Engl J Med 1991;325:1534–8.).",
author = "Judith Falloon and Joseph Kovacs and Donna O'neill and Michael Polis and Henry Masur and Irwin Feuerstein and Davey, {Richard T.} and Lane, {H. Clifford} and Walter Hughes and Danny Lancaster and Mack Land and Michael Rogers and Stephen Lafon and Carmelita Tuazon and Michael Dohn and Stephen Greenberg",
year = "1991",
month = "11",
day = "28",
doi = "10.1056/NEJM199111283252202",
language = "English (US)",
volume = "325",
pages = "1534--1538",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome

AU - Falloon, Judith

AU - Kovacs, Joseph

AU - O'neill, Donna

AU - Polis, Michael

AU - Masur, Henry

AU - Feuerstein, Irwin

AU - Davey, Richard T.

AU - Lane, H. Clifford

AU - Hughes, Walter

AU - Lancaster, Danny

AU - Land, Mack

AU - Rogers, Michael

AU - Lafon, Stephen

AU - Tuazon, Carmelita

AU - Dohn, Michael

AU - Greenberg, Stephen

PY - 1991/11/28

Y1 - 1991/11/28

N2 - The drug 566C80 is an investigational hydroxynaphthoquinone that is active against Pneumocystis carinii in vitro and in animal models. Initial studies in humans indicate that 566C80 is safe and has adequate bioavailability after oral administration. We conducted an open-label trial of 566C80 in 34 adults with the acquired immunodeficiency syndrome (AIDS) and untreated pneumocystis pneumonia. All the patients had a partial pressure of arterial oxygen of at least 60 mm Hg while breathing room air. They were enrolled sequentially in three cohorts taking 566C80 at different dosages, all administered orally: 750 mg three times daily for 5 days, then twice daily for 16 days; 750 mg three times daily for 21 days; and 750 mg four times daily for 21 days. All 34 patients survived, and 27 (79 percent) were successfully treated with 566C80 alone. The mean partial pressure of oxygen in 33 patients was 78 mm Hg at entry and 93 mm Hg after the course of 566C80 (P<0.001). In five patients (15 percent) the drug was discontinued because of lack of response. In four patients (12 percent), the drug was discontinued because of toxicity (fever and rash in two patients each). In two of these, treatment was considered to have succeeded because 566C80 was not discontinued because of toxicity until after day 14. Five of the successfully treated patients had rashes that resolved despite continued therapy. In nine patients, serum alanine aminotransferase levels rose above 100 U per liter. During the first three months after the completion of therapy, pneumocystis pneumonia recurred in 4 of the 27 successfully treated patients, and another 3 patients had recurrences between month 3 and month 6 of follow-up. The mean (±SEM) steady-state plasma levels of 566C80 were similar in the three cohorts: 16.3±2.10, 20.4±2.48, and 18.9±3.08 μg per milliliter in the patients taking the drug twice daily, three times daily, and four times daily, respectively. From these preliminary data, the investigational compound 566C80 appears to be a safe, effective, and well-tolerated therapy for P. carinii pneumonia of mild-to-moderate severity in patients with AIDS. (N Engl J Med 1991;325:1534–8.).

AB - The drug 566C80 is an investigational hydroxynaphthoquinone that is active against Pneumocystis carinii in vitro and in animal models. Initial studies in humans indicate that 566C80 is safe and has adequate bioavailability after oral administration. We conducted an open-label trial of 566C80 in 34 adults with the acquired immunodeficiency syndrome (AIDS) and untreated pneumocystis pneumonia. All the patients had a partial pressure of arterial oxygen of at least 60 mm Hg while breathing room air. They were enrolled sequentially in three cohorts taking 566C80 at different dosages, all administered orally: 750 mg three times daily for 5 days, then twice daily for 16 days; 750 mg three times daily for 21 days; and 750 mg four times daily for 21 days. All 34 patients survived, and 27 (79 percent) were successfully treated with 566C80 alone. The mean partial pressure of oxygen in 33 patients was 78 mm Hg at entry and 93 mm Hg after the course of 566C80 (P<0.001). In five patients (15 percent) the drug was discontinued because of lack of response. In four patients (12 percent), the drug was discontinued because of toxicity (fever and rash in two patients each). In two of these, treatment was considered to have succeeded because 566C80 was not discontinued because of toxicity until after day 14. Five of the successfully treated patients had rashes that resolved despite continued therapy. In nine patients, serum alanine aminotransferase levels rose above 100 U per liter. During the first three months after the completion of therapy, pneumocystis pneumonia recurred in 4 of the 27 successfully treated patients, and another 3 patients had recurrences between month 3 and month 6 of follow-up. The mean (±SEM) steady-state plasma levels of 566C80 were similar in the three cohorts: 16.3±2.10, 20.4±2.48, and 18.9±3.08 μg per milliliter in the patients taking the drug twice daily, three times daily, and four times daily, respectively. From these preliminary data, the investigational compound 566C80 appears to be a safe, effective, and well-tolerated therapy for P. carinii pneumonia of mild-to-moderate severity in patients with AIDS. (N Engl J Med 1991;325:1534–8.).

UR - http://www.scopus.com/inward/record.url?scp=0026410831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026410831&partnerID=8YFLogxK

U2 - 10.1056/NEJM199111283252202

DO - 10.1056/NEJM199111283252202

M3 - Article

VL - 325

SP - 1534

EP - 1538

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -